Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | UGCG | Q16739 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414881 | 0.89 | CYP17A1 (0.45) | CYP17A1CYP2C8CYP3A4 | |
| SCHEMBL1414812 | 0.89 | CYP17A1 (0.58) | CYP17A1CYP2C8CYP3A4 | |
| SCHEMBL1414934 | 0.80 | CYP17A1 (0.41) | CYP17A1CYP2C8 | |
| SCHEMBL1414829 | 0.79 | CYP17A1 (0.58) | CYP17A1CYP2C8CYP3A4 | |
| SCHEMBL5751159 | 0.73 | ACSS2 (0.39) | CYP17A1CASR | |
| SCHEMBL1415054 | 0.73 | CYP17A1 (0.57) | CYP17A1CYP2C8CYP3A4 | |
| SCHEMBL8540731 | 0.72 | KIF11 (0.46) | CYP3A4 | |
| SCHEMBL4025339 | 0.71 | CYP17A1 (0.53) | CYP17A1CYP3A4CASR | |
| SCHEMBL31285478 | 0.70 | ENPP2 (0.36) | — | |
| SCHEMBL1414930 | 0.70 | CYP17A1 (0.70) | CYP17A1CYP2C8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1344777-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-6960586-B2 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1344777-A1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | CYP17A1, HSD17B7, CYP51A1 | CYP17A1 1/4885CYP2C8 137/4885CYP3A4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.